Advertisement
Pharmaceutical Companies
Subscribe to Pharmaceutical Companies

The Lead

Lawsuit says Novartis’ Gleevec patent infringement suit a ‘sham’

July 1, 2015 10:31 am | by Jonathon Shacat, FDA | News | Comments

Two institutional buyers of Gleevec want to stop its manufacturer, Novartis, from delaying generic competition of the blockbuster leukemia drug, saying a patent litigation settlement between the brandmaker and generics maker Sun Pharma ...

Bristol-Myers Squibb will win big with melanoma combination immunotherapy

June 24, 2015 3:49 pm | by GlobalData | News | Comments

Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by...

Bristol-Myers Squibb is an overvalued company in an expensive sector

June 18, 2015 12:35 pm | by Seeking Alpha | News | Comments

In my view, the market is set to crash at a certain point in the future. The reason? If the FED...

Lack of a MERS vaccine frustrates scientists

June 18, 2015 12:28 pm | by Kate Kelland and Ben Hirschler, Reuters | News | Comments

Three years after the mysterious MERS virus first emerged in humans, scientists and drugmakers...

View Sample

FREE Email Newsletter

Sandoz seeks to overturn $38M judgement

June 17, 2015 11:49 am | by The Associated Press | News | Comments

A drug manufacturer is asking the Mississippi Supreme Court to reverse a $38.2 million judgment for the state in a Medicaid drug-pricing lawsuit.

Botox maker Allergan adds 'double-chin' drug with $2.1B deal

June 17, 2015 11:32 am | by The Associated Press | News | Comments

Botox maker Allergan Plc. is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as "double chin".

Novartis gains FDA approval for childhood blood disorder drug

June 12, 2015 11:08 am | by PRNewswire | News | Comments

ITP affects as many as 5 in 100,000 children each year and is characterized by a low platelet count.

Advertisement

Carna announces collaboration with J&J

June 11, 2015 11:22 am | by Business Wire | News | Comments

Carna Biosciences today announced a worldwide licensing agreement with Janssen Biotech to further develop and commercialize compounds from one of Carna Bioscience’s small molecule protein kinase inhibitor programs.

Johnson & Johnson starts project to prevent Type 1 diabetes

June 11, 2015 11:04 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

It's the healthcare giant's first project under its ambitious initiative to prevent or at least intercept and reduce harm from many diseases.

FDA panel backs first-in-class cholesterol drug

June 10, 2015 11:55 am | by Matthew Perrone, AP Health Writer | News | Comments

Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with the caveat that more data is needed about its long-term ability to reduce heart attacks.

J&J opens new schizophrenia project

June 9, 2015 11:20 am | by PR Newswire | News | Comments

The project will create a new forum for collaborative analysis of Janssen's clinical trial data with data available from the National Institutes of Health (NIH) about schizophrenia.

Rutgers research promises ‘revolution’ in pharmaceutical manufacturing

June 4, 2015 4:17 pm | by Meagan Parrish, Editor, Chem.Info | News | Comments

A $6 million gift from Janssen Pharmaceuticals will help spur Rutgers’ research into “revolutionary” continuous manufacturing. 

Advertisement

CEO: Pfizer doubles share of drug market for breast cancer

June 4, 2015 11:52 am | by Andy Szal, Digital Reporter | News | Comments

Promising trial results for a new drug designed to treat aggressive breast cancer helped Pfizer double its share of that market, according to CEO Ian Read.

AstraZeneca reviewing psoriasis drug following suicide concerns

June 2, 2015 4:10 pm | by Andy Szal, Digital Reporter | News | Comments

The drug — named brodalumab — led to suicidal thoughts among trial patients, which could result in regulators attaching a warning label to the product.

Perrigo to acquire GSK OTC brands

June 2, 2015 12:27 pm | by PR Newswire | News | Comments

Perrigo will acquire a portfolio of well-established over-the-counter brands from GlaxoSmithKline Consumer Healthcare.

J&J pipeline forecasting 10 new products worth $1B

June 2, 2015 12:14 pm | by PR Newswire | News | Comments

Senior leaders announced plans to file for regulatory approval of more than 10 new products between 2015 and 2019.

Bayer Announces New Name for Plastics Division

June 1, 2015 5:11 pm | by Andy Szal, Digital Reporter | News | Comments

The company’s other operations, including health care and crop science, are in the midst of an overhaul as Bayer transitions to a “pure life-sciences company."

Advertisement

Teva to pay $1.2 billion in drug-delay settlement

May 29, 2015 11:15 am | by MATTHEW PERRONE, AP Health Writer | News | Comments

Federal regulators announced Thursday that Teva Pharmaceuticals will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil.

Pfizer offers $3 million in breast cancer grants

May 28, 2015 11:17 am | by Business Wire | News | Comments

The multi-year program, which will award a total of up to $3 million in grants to investigators in the United States, is an extension of Pfizer’s Advancing Science through Pfizer Investigator Research Exchange initiative.

Halozyme, Ventana enter development agreement

May 27, 2015 10:43 am | by PRNewswire | News | Comments

Under the agreement, Ventana will develop an in vitro diagnostic using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval. The target will be metastatic pancreatic cancer patients.

Novartis offers pipeline update

May 27, 2015 10:32 am | by PRNewswire | News | Comments

Data will demonstrate advances in research in a variety of cancer types, including melanoma, lung, breast, kidney and blood cancers. The goal of these products will be to improve and possibly extend the lives of people with solid and hematologic tumors.

Endo’s Purchase of Par Pharma Shakes up the Industry

May 21, 2015 11:03 am | News | Comments

US Pharma M&A activity has yet to show any signs of a slowdown after the $8.1bn exit of Par Pharma by TPG to Endo was announced on Monday. The US Pharma industry has seen 39 deals valued at US$ 77.3bn to-date, three more deals announced ...

Novartis Investigational Drug Significantly Improved Lung Function

May 20, 2015 12:02 pm | by PR Newswire | News | Comments

Today, Novartis announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149 (indacaterol/glycopyrronium) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In the US ...

J&J Pharmaceuticals Announces 10 filings for Blockbuster Drugs by 2019

May 20, 2015 10:43 am | News | Comments

At a meeting today with analysts, Johnson & Johnson's Janssen Pharmaceuticals announced plans for regulatory approval of more than 10 new drugs between 2015 and 2019, each with the potential to generate at least $1B in sales, in addition to ...

Pfizer Trying To Overcome Patent Cliff

May 20, 2015 10:33 am | News | Comments

Pfizer Inc. is trying to overcome the patent cliff that has seen its recent quarter results suffer by adopting its classic strategy of forging marketing alliances and making acquisitions. The pharma giant recently agreed to buy a stake in Dutch biotechnology company AM-Pharma....

Investigational Hep C Drugs Receive Breakthrough Therapy Designation

May 20, 2015 10:20 am | by Business Wire | News | Comments

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) patients.

J&J Settles $7.8 Million Lawsuit

May 19, 2015 10:35 am | by AP | News | Comments

Three years ago a jury found that a subsidiary, Janssen Pharmaceutical, committed Medicaid fraud and violated a state law in its labeling and marketing of Risperdal. A $1.2 billion fine was initially imposed on Johnson & Johnson.

Eagle Pharmaceuticals Receives Patent for Rapid Infusion Product

May 19, 2015 8:59 am | by Business Wire | Teva Pharmaceuticals Usa | News | Comments

Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. Patent No. 9,034,908, which pertains to the use of the bendamustine hydrochloride (HCl) formulation administered in a 50mL bag within ten minutes.

FTC Seeks More Info From Pfizer About Hospira Acquisition

May 15, 2015 12:04 pm | by Pfizer Inc. | News | Comments

Pfizer Inc. today announced that it has received a request for additional information from the FTC with respect to its previously announced proposed acquisition of Hospira.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading